11
Resistance in Clinical
Isolates Adverse Events Evidence Supporting Efficacy
Not reported Minimally absorbed Multiple RCTs; U.S. FDA-Approved
One clinical isolate with
increased MIC
Minimally absorbed Two Phase III RCT comparisons to
vancomcyin; U.S. FDA-Approved
Increased MIC reported
in some studies; Hetero-
resistance also reported
Neuropathy, Nausea Multiple RCTs
Not reported GI symptoms • Small RCT comparison to
vancomycin and a modest
sized RCT comparison to
metronidazole
Reported to develop in
vivo resistance
GI symptoms • Modest-sized RCT comparison to
metronidazole and a small RCT
comparison to vancomycin
Potential for
development of high-
level resistance
Minimally absorbed • 1 small RCT comparison to
vancomycin for primary treatment
• Case series and 1 RCT pilot study
show promise for use as a post-
vancomycin 'chaser' strateg y in
management of recurrent CDI
Not reported GI symptoms Case reports and small case series
Increasing resistance
noted
Minimally
absorbed, poor taste
Two small RCT comparisons to
vancomycin
